SUMO2 and cancer: Notably, BioRank effectively prioritized well-established cancer genes such as TP53, ESR1, EGFR, AKT1, and MYC at top ranks, while also identifying less-explored but potentially promising candidates such as GRB2, SUMO2, RELA, TRIM28, FN1, ALB, PNP, CCR3, CDH7, SOX1, and CCL18.